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Abstract 
Background: Verification of cerebrospinal fluid (CSF) biomarkers for multiple sclerosis and other neurological 
diseases is a major challenge due to a large number of candidates, limited sample material availability, disease and 
biological heterogeneity, and the lack of standardized assays. Furthermore, verification studies are often based on a 
low number of proteins from a single discovery experiment in medium-sized cohorts, where antibodies and surrogate 
peptides may differ, thus only providing an indication of proteins affected by the disease and not revealing the bigger 
picture or concluding on the validity of the markers. We here present a standard approach for locating promising 
biomarker candidates based on existing knowledge, resulting in high-quality assays covering the main biological 
processes affected by multiple sclerosis for comparable measurements over time.
Methods: Biomarker candidates were located in CSF-PR (proteomics.uib.no/csf-pr), and further filtered based on 
estimated concentration in CSF and biological function. Peptide surrogates for internal standards were selected 
according to relevant criteria, parallel reaction monitoring (PRM) assays created, and extensive assay quality testing 
performed, i.e. intra- and inter-day variation, trypsin digestion status over time, and whether the peptides were able to 
separate multiple sclerosis patients and controls.
Results: Assays were developed for 25 proteins, represented by 72 peptides selected according to relevant guide-
lines and available literature and tested for assay peptide suitability. Stability testing revealed 64 peptides with low 
intra- and inter-day variations, with 44 also being stably digested after 16 h of trypsin digestion, and 37 furthermore 
showing a significant difference between multiple sclerosis and controls, thereby confirming literature findings. Cali-
bration curves and the linear area of measurement have, so far, been determined for 17 of these peptides.
Conclusions: We present 37 high-quality PRM assays across 21 CSF-proteins found to be affected by multiple 
sclerosis, along with a recommended workflow for future development of new assays. The assays can directly be 
used by others, thus enabling better comparison between studies. Finally, the assays can robustly and stably monitor 
biological processes in multiple sclerosis patients over time, thus potentially aiding in diagnosis and prognosis, and 
ultimately in treatment decisions.
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Background
There are currently only a few biomarkers for mul-
tiple sclerosis (MS) in clinical use, including MRI 
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JC viral antibody titers and neurofilament light, as sum-
marized in a recent review [1]. However, both in-house 
discovery studies and available literature suggest numer-
ous additional biomarkers representing several of the 
processes and pathways active in MS, such as inflam-
mation and neurodegeneration [2–5]. Such findings 
however require further verification via robust targeted 
assays, e.g. through parallel reaction monitoring (PRM) 
using high-quality stable isotope labelled heavy peptides 
[6–8].
The process of developing robust targeted assays in 
turn requires the consideration of a multitude of factors 
in order to ensure the quality and relevance of the assays, 
especially when the goal is to provide absolute protein 
measurements that would allow the consecutive analyses 
of proteins both across different labs and over time. This 
will make it possible to monitor specific pathological pro-
cesses occurring in individual MS patients and thereby 
gain a deeper insight into the processes active at the vari-
ous stages of the disease, which in turn would be a valu-
able tool in diagnosis, prognosis and treatment decisions.
Cerebrospinal fluid (CSF) is a commonly used body 
fluid in studies of neurological diseases, such as MS. 
Although not as easily accessible as serum/plasma, it is 
likely to better reflect ongoing neurological processes as 
it is in direct contact with the central nervous system [9]. 
However, large scale biomarker verification of discovery 
experiments has proven difficult in CSF and results are 
rarely consistent between studies. Likely reasons for this 
are methodological differences, large individual varia-
tions in total CSF protein concentrations [10] as well as 
significant heterogeneity in neurological diseases [11–
13]. As a consequence, the quantitative data from indi-
vidual biomarker discovery and verification studies do 
not always overlap and cannot directly and easily be com-
pared and combined [14]. The large dynamic range of 
proteins in CSF also leads to challenges when measuring 
small disease-related changes in low abundant proteins 
[13, 15], especially vulnerable to small methodological 
variations and inaccuracies. Combined with relatively 
low patient numbers in most studies, it becomes almost 
impossible to conclude regarding a biomarker’s potential, 
and thus move from the biomarker discovery phase to 
clinically useful biomarkers. It is therefore crucial to cre-
ate robust targeted assays for accurate measurements of 
biomarker candidates.
Here we describe a suggested standard approach for 
the selection of candidate biomarkers in CSF for MS, and 
detail the required validation of PRM assays for absolute 
quantification of 25 proposed biomarker candidates. The 
validation includes (i) intra- and inter-day variation, (ii) 
the effect of trypsin digestion time, and (iii) verification 
of the separation capability between MS and controls 
observed from the literature [14]. Additionally, the lin-
earity around the typical concentration of target pep-
tides was determined and corresponding response curves 
determined. The validated assays are ready to be used in 
large-scale analysis of patient samples and the presented 
standard approach for PRM assay development can also 
be applied for other neurological diseases.
Results—from biomarker candidates 
to high‑quality PRM assays
The following sections describes the steps from poten-
tial literature-based biomarker candidates from CSF-PR 
(proteomics.uib.no/csf-pr), to the list of the most prom-
ising proteins and peptides to include in robust high-
quality PRM biomarker assays for MS (Fig. 1).
Selection of proteins and peptides
Literature curation using CSF‑PR
The recently published CSF-PR 2.0 [14] contains struc-
tured and searchable quantitative data for thousands of 
CSF-proteins from close to 100 datasets related to MS, 
Alzheimer’s disease (AD) and Parkinson’s disease (PD). 
The data in CSF-PR comes from mass spectrometry stud-
ies that have passed certain filters notably related to (i) 
methodology (bottom-up shotgun or targeted proteom-
ics for main experiment; ELISA for verification), (ii) 
number of patients (n ≥ 5 in each disease group; if using 
pools, ≥ 3 pools for each disease group and n ≥ 20 total), 
and (iii) sample type (CSF from living subjects).
The biomarker selection was conducted by merging 
relevant datasets from MS and control subcategories in 
CSF-PR and extracting the proteins found to be signifi-
cantly different in abundance in the majority of studies, 
according to certain criteria. See “Materials and meth-
ods” section for more details. The CSF-PR data extraction 
resulted in an initial list of 133 proteins (Additional file 1: 
Table  S1), representing promising biomarker candidates 
for MS quantified in several experiments where various 
degree of fractionation had been used. Separately, we also 
collected a list of proteins that were changed between 
MS and control, but quantified in only one study in CSF-
PR (Additional file  2: Table  S2). Most of the latter were 
proteins from our recent discovery study [5], where both 
depletion and extensive peptide fractionation was per-
formed, and they are therefore likely the lowest abundant 
proteins possible to quantify by current mass spectrom-
etry proteomics technology.
Identifying proteins within the suitable dynamic range 
of CSF
An important condition for assay development is to 
be able to perform PRM quantitation in crude CSF 
without high-abundant protein depletion or peptide 
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Fig. 1 The main steps in developing robust PRM assays for CSF biomarkers related to MS
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fractionation. In order to find the proteins most likely 
fulfilling this condition, a CSF fractionation test was car-
ried out, where the trypsin digested CSF-proteome was 
separated into eleven fractions and analysed by data-
dependent acquisition (DDA) MS/MS, resulting in 1194 
proteins. We estimate that PRM can be ten times more 
sensitive than what can be identified in a regular DDA 
shotgun experiment [16]. Therefore, the identification 
of a protein in a 20 µg un-depleted sample, fractionated 
into 11 fractions (first fraction usually does not contain 
peptides), indicates that the protein can be quantified 
by PRM in crude CSF. A total of 120 of the 132 proteins 
extracted from CSF-PR were identified in the DDA analy-
sis (Additional file 3: Table S3) and passed on to the next 
steps in the assay development. All of the proteins identi-
fied in the DDA analysis can be found in Additional file 4: 
Table S4.
Biological processes and categories
A closer inspection of the 120 proteins revealed several 
groups of related proteins with similar names, func-
tions and abundance relationship between MS and con-
trol, e.g. immunoglobulin proteins, cadherin proteins, 
receptor-type tyrosine-protein phosphatases, and SLIT 
and NTRK-like proteins. These proteins are likely to be 
involved in the same biological processes, and therefore 
developing individual PRM assays for all these proteins 
is probably not necessary, as recent studies indicate that 
such related proteins are most-often affected in the same 
manner [4, 5].
A representative selection of the 120 proteins from 
Additional file  3: Table  S3 was made based on available 
information from CSF-PR, i.e. the number and propor-
tion of studies where changes between MS and Non-MS 
was observed. Additionally, the large network of inter-
acting and significantly changed proteins between MS 
and other neurological diseases (OND) generated in our 
recent publication [5] was utilized to select one or two 
proteins as representatives of the various biological pro-
cesses likely to be affected in MS. These processes include 
e.g. (i) inflammation—a hallmark of the MS disease, (ii) 
extracellular matrix organization proteins—providing 
structure and support for developing neurons (e.g. col-
lagens and proteoglycans), (iii) ephrin proteins—involved 
in neuron development, myelination and axonal guid-
ance, and (iv) cadherins—cell adhesion proteins known 
to be involved in de- and re-myelination. Additional pro-
teins found especially interesting based on keywords in 
UniProt [17] or our own previous experiments were also 
included. All the steps in the protein selection process is 
outlined in Fig. 2, and the 25 selected proteins are shown 
in Table 1.
Peptide selection
Selecting peptides to represent the proteins under inves-
tigation, so-called surrogate or signature peptides, is a 
crucial step in the development of a targeted proteom-
ics assay, and a number of criteria determines if a pep-
tide is suitable [19, 20]. Here, the initial peptide selection 
was done mainly based on peptide data available from 
CSF-PR combined with general guidelines for selecting 
peptides for targeted proteomics [6, 19–21]. As a rule, 
three- to four peptides were selected per protein and the 
corresponding isotopically heavy labelled versions were 
ordered. However, not all peptides were found with an 
acceptable signal in the MS/MS analysis, hence, some 
of the proteins are only represented by a single peptide. 
For one protein (chitinase-3-like protein 1), more than 
three heavy peptides were ordered given that this protein 
has been reported as particularly interesting in relation 
to MS [22–28], and we had previously experienced that 
this protein could be challenging to quantify (data not 
shown). In total, 72 peptides were selected to represent 
the 25 proteins (Table 2). Further testing was performed 
to determine whether they were truly suitable as protein 
surrogates, as outlined below.
Peptide stability testing
PRM assays ought to have low intra- and inter-day vari-
ation in order to allow comparable quantitative meas-
urements over time. To test this, PRM experiments with 
two replicates were processed each day across 5  days, 
and the intra- and inter-day coefficient of variation (CV) 
was calculated for all the 72 peptides. Most of the pep-
tides displayed an intra- and inter-day CV of less than 
20% (Fig.  3). Only eight of the initial 72 peptides had a 
CV above 20%, with seven from chitinase-3-like protein 
1 (CH3L1), failing only the inter-day CV, and one from 
Seizure 6-like protein 2 (SEZ6L2), failing both intra- and 
inter-day CV. Notably, none of the peptides from CH3L1 
showed an acceptable inter-day CV. Peptides not fulfill-
ing the intra- and inter-day CV limits were discarded, 
(See figure on next page.)
Fig. 2 The main steps in the identification and selection of biomarker candidate proteins for inclusion in the PRM assays. Screenshots are from 
CSF-PR [14], PPI network is from [5] and other figures are from Servier Medical Art licensed under a Creative Commons Attribution 3.0 Unported 
License. TMT = tandem mass tag, DDA = data dependent acquisition, MM-RP AX = mixed-mode reversed-phase anion exchange [18], GO = gene 
ontology, ECM = Extracellular matrix
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Table 1 The 25 proteins selected for assay development
Accession Name Network* CSF‑PR score** Datasets*** Selected keywords from UniProt 
and Gene Ontology
P51693 Amyloid-like protein 1 Yes − 50 1 ↑ [56]
1 – [57]
4 ↓ [4, 5, 56]
Postsynaptic function, neurite outgrowth, 
neuronal apoptosis
P61769 Beta-2-microglobulin Yes 60 3 ↑ [4, 5]
2 – [25, 57]
Component of the class I MHC, antigen 
presentation, innate immune response
P55290 Cadherin-13 Yes − 75 3 ↓ [4, 5]
1 – [25]
Cell adhesion, negative regulator of neural 
cell growth
P16070 CD44 antigen Yes 75 3 ↑ [4, 5]
1 – [25]
Mediates cell–cell and cell–matrix interac-
tions, cell migration
P36222 Chitinase-3-like protein 1 70 8 ↑ [4, 5, 24, 25, 56]
1 – [22]
1 ↓ [56]
Lectin that binds glycans, no chitinase 
activity, inflammatory response, mac-
rophage differentiation
Q15782 Chitinase-3-like protein 2 100 6 ↑ [4, 5, 25] Lectin that binds glycans, no chitinase 
activity, carbohydrate metabolic process
P10645 Chromogranin-A − 50 4 ↓ [4, 5, 22]
4 – [2, 25, 57]
Innate immune response, defence 
response (fungus, bacterium), negative 
regulation of neuron death
P12111 Collagen alpha-3(VI) chain Yes 50 2 ↑ [4, 5]
2 – [4, 25]
Cell binding/adhesion, extracellular matrix 
organization
P02747 Complement C1q subcomponent 
subunit C
Yes 100 3 ↑ [4, 5] Complement system, immune response
P00736 Complement C1r subcomponent Yes 75 3 ↑ [4, 5]
1 – [25]
Complement system, immune response
P54764 Ephrin type-A receptor 4 Yes − 100 5 ↓ [4, 5, 56] RTK signalling, promiscuous, prevents 
axonal regeneration, cell adhesion, cell 
signalling, repair after injury in the nerv-
ous system, axonal guiding
Q6MZW2 Follistatin-related protein 4 − 75 3 ↓ [4, 5]
1 – [25]
Negative regulation of dendritic spine 
development and collateral sprouting
P48058 Glutamate receptor 4 Yes − 50 2 ↓ [4, 5]
2 – [4, 25]
Excitatory synaptic transmission
P01591 Immunoglobulin J chain 67 2 ↑ [4], 1 – [5] Links monomers of IgM or IgA, antigen 
binding, immune response
Q92876 Kallikrein-6 Yes − 60 1 ↑ [56]
2 − [–2, 25]
7 ↓ [2, 4, 5, 22, 56, 57]
Serine protease, Indicated in AD, regula-
tion of axon outgrowth after injury, 
myelination
P32004 Neural cell adhesion molecule L1 Yes − 75 3 ↓ [4, 5]
1 – [25]
Nervous system development, neuron–
neuron adhesion, neuronal migration, 
axonal growth, synaptogenesis
Q9ULB1 Neurexin-1 67 2 ↓ [4, 5]
1 – [4]
Cell surface protein, cell–cell interactions, 
axon guidance, signal transmission, 
neurotransmitter release
Q9P2S2 Neurexin-2 − 75 3 ↓ [4, 5]
1 – [25]
Neuronal cell surface protein, cell recogni-
tion, adhesion, signalling
Q92823 Neuronal cell adhesion molecule − 75 3 ↓ [4, 5]
1 – [25]
Neurite outgrowth. cell–cell contacts 
between Schwann cells and axons. for-
mation and maintenance of the nodes 
of Ranvier on myelinated axons.
Q99983 Osteomodulin Yes 75 3 ↑ [4, 5]
1 – [25]
Biomineralization processes, cell adhesion, 
extracellular matrix
Q9UHG2 ProSAAS Yes − 75 3 ↓ [4, 5]
1 – [25]
Control of the neuroendocrine secretory 
pathway.
P23468 Receptor-type tyrosine-protein phos-
phatase delta
Yes − 100 2 ↓ [4, 5] Phosphatase, pre- and post-synaptic dif-
ferentiation of neurons
O00584 Ribonuclease T2 100 3 ↑ [4, 5] Lysosomal degradation of ribosomal RNA
P13521 Secretogranin-2 − 57 4 ↓ [4, 5, 22]
3 – [2, 25]
Neuroendocrine secretory granule protein
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resulting in 64 peptides from 24 proteins retained. 
Detailed results from this experiment can be found in 
Additional file 5: Table S5.
Peptide digestion testing
In order to create assays for absolute protein concen-
trations in CSF samples, it is important to investigate 
how the trypsin incubation time affects the quantita-
tive results. The main question is whether the detected 
amount of a peptide continues to increase after complet-
ing a standard trypsin digestion protocol with 16 h diges-
tion time (see “Materials and methods” section), as then 
the absolute concentration of the corresponding protein 
cannot be determined via such a standard digestion pro-
tocol using the given peptide.
The experiment investigated five different digestion 
times (1, 5, 16, 24 and 30 h), each with three replicates, 
and was repeated three times. A peptide was considered 
stably digested after 16 h if the percentage change from 
16 to 24 h and from 16 to 30 h was both less than 20%. 
In addition, the resulting peaks had to be satisfactory 
with regards to intensity, interference and shape, evalu-
ated through the Skyline [29] data analysis. A total of 44 
peptides, with at least one peptide from each of the 24 
proteins, passed the digestion test. In other words, 20 
peptides, but no proteins, were discarded based on this 
test.
How the peptides changed (ratio light/heavy) after 
16 h is illustrated in Fig. 4a, b, where red dots represent 
the peptides who failed the test. Examples of observed 
peptide profiles for two selected proteins are shown in 
Fig. 5a, b.
As can be seen from Fig.  5a, all of the three peptides 
from neuronal cell adhesion molecule show limited 
increase after 16  h of digestion, i.e. they all passed the 
test. However, some proteins demonstrated an increase 
in peptide amount after 16 h and/or a varying digestion 
profile for the different peptides. As an example, we see 
that peptide SLPSEASEQYLTK in Fig.  5a appears to be 
readily digested already after 1  h. Other proteins had 
some peptides passing and some failing the digestion 
test. In Fig.  5b, we see that one peptide for the protein 
Seizure-6-like protein 2 increase in amount up to 16  h 
of digestion, and then no increase beyond 20% is found 
(peptide passed), while a different peptide from the same 
protein continue to increase after 16 h, thereby failing the 
test, notably with a high variation in the minimum and 
maximum values.
All the data from this experiment is available in Addi-
tional file 6: Table S6 and the complete digestion profile 
for all peptides can be found in Additional file 7: Fig. S1 
and peptide abundance change at all measured time 
points are in Additional file 8: Fig. S2.
RRMS vs non‑inflammatory controls
To test whether the changes indicated in CSF-PR 
between MS and Non-MS could be reproduced, a small 
PRM study was conducted using six pools of CSF from 
MS (three pools of seven RRMS patients) and control 
(three pools of seven OND patients) patients. These 
pools have previously been analysed in-depth by shot-
gun TMT-based proteomics [5], and were selected to test 
how well the optimized PRM assays reflect the differ-
ences between the two patient categories. 
The majority of the 44 tested peptides showed similar 
regulation trends as previously reported in the literature 
(Fig. 6), but a couple of the peptides were not found sig-
nificantly changed in this study (Osteomodulin—two 
peptides, Complement C1q subcomponent subunit C—
one peptide, Collagen alpha-3(VI) chain—one peptide, 
CD44 antigen—one peptide), and two peptides showed 
the opposite direction of regulation compared to CSF-
PR (Complement C1q subcomponent subunit C—one 
peptide, Complement C1r subcomponent—one peptide). 
These were therefore discarded from further assay devel-
opment. In conclusion, seven of 44 tested peptides failed 
this test.
We concluded that the remaining 37 peptides were 
suitable to reflect the previously reported regulations, 
and therefore represent the most promising biomarkers 
Relevant details for the selected proteins, such as whether or not they were found in the main protein–protein interaction network in our recent in-depth discovery 
study [5], their CSF-PR score, studies that found them increased or decreased in MS vs. Non-MS and selected gene ontology terms and keywords related to their 
function. Arrows pointing down: decreased abundance in MS; arrows pointing up: increased abundance in MS; Dash: no change in abundance between MS and 
Non-MS
* Proteins found in the main protein interaction network from [4]
** The score for MS vs. Non-MS calculated by CSF-PR according to the equation described in “Materials and methods” section
*** Multiple datasets can be from the same paper
Table 1 (continued)
Accession Name Network* CSF‑PR score** Datasets*** Selected keywords from UniProt 
and Gene Ontology
Q6UXD5 Seizure 6-like protein 2 − 50 2 ↓ [4, 5]
2 – [4, 25]
Specialized ER function in neurons?
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Table 2 The 72 signature peptides selected for the 25 proteins
Accession Protein name # Peptides Peptide sequence(s)
P51693 Amyloid-like protein 1 3 WEPDPQR
FQVHTHLQVIEER
GFPFHSSEIQR
P61769 Beta-2-microglobulin 2 VEHSDLSFSK
VNHVTLSQPK
P55290 Cadherin-13 3 YEVSSPYFK
VNSDGGLVALR
INENTGSVSVTR
P16070 CD44 antigen 3 FAGVFHVEK
ALSIGFETCR 
YGFIEGHVVIPR







Q15782 Chitinase-3-like protein 2 2 LVCYFTNWSQDR
LLLTAGVSAGR 
P10645 Chromogranin-A 3 ILSILR
SGELEQEEER
EDSLEAGLPLQVR
P12111 Collagen alpha-3(VI) chain 2 EVYTFASEPNDVFFK
WYYDPNTK
P02747 Complement C1q subcomponent subunit C 3 QTHQPPAPNSLIR
FNAVLTNPQGDYDTSTGK
TNQVNSGGVLLR




P54764 Ephrin type-A receptor 4 3 VYPANEVTLLDSR
NLAQFPDTITGADTSSLVEVR
GLNPLTSYVFHVR
Q6MZW2 Follistatin-related protein 4 3 GPDVGVGESQAEEPR
FDDYNSDSSLTLR
VLQSIGVDPLPAK
P48058 Glutamate receptor 4 3 NTDQEYTAFR
LQNILEQIVSVGK
EYPGSETPPK
P01591 Immunoglobulin J chain 2 SSEDPNEDIVER
IIVPLNNR
Q92876 Kallikrein-6 3 LSELIQPLPLER
TADGDFPDTIQCAYIHLVSR
DSCQGDSGGPLVCGDHLR
P32004 Neural cell adhesion molecule L1 3 INGIPVEELAK
AQLLVVGSPGPVPR
EGPGEAIVR
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for MS. The complete results from this test is found in 
Additional file 9: Table S7.
Final assay peptides
After all the steps detailed above, we finally arrived at a 
list of 37 peptides from 21 proteins for which promising 
absolute quantitative PRM assays could be developed 
(Table  3). These represent the best surrogates to pre-
cisely and reproducibly quantitate proteins affected by 
MS. A complete table of all the tested peptides, impor-
tant results and data from each experiment is collected in 
Additional file 10: Table S8, and a protein level overview 
of the number of peptides passing the various tests can 
be found in Additional file 11: Table S9.
Calibration curves
To ensure that the peptides could be accurately quan-
tified by PRM mass spectrometry around the level of 
its observed concentration in CSF, calibration curves 
determining the linear areas of quantification have to 
be determined. Calibration curves have so far been gen-
erated for 17 of the peptides passing the initial testing 
and the work is ongoing. Rat plasma was used as matrix 
with varying amounts of synthetic light peptide and sta-
ble spike-in of heavy surrogate peptide. The linear area 
was determined by weighed least squares regression. For 
further details see “Materials and methods” section. An 
example of a calibration curve is shown in Fig. 7 and all 
of the calibration curves developed so far are provided in 
Additional file 12: Fig. S3 and additional details related to 
slope, intercept and linear areas are in Additional file 10: 
Table S8.
Table 2 (continued)
Accession Protein name # Peptides Peptide sequence(s)
Q9ULB1 Neurexin-1 3 DLFIDGQSK
SDLYIGGVAK
LPDLISDALFCNGQIER
Q9P2S2 Neurexin-2 3 LSALTLSTVK
GATADPLCAPAR
AIVADPVTFK
Q92823 Neuronal cell adhesion molecule 3 AETYEGVYQCTAR 
SLPSEASEQYLTK
VFNTPEGVPSAPSSLK
Q99983 Osteomodulin 2 IDYGVFAK
LLLGYNEISK
Q9UHG2 ProSAAS 1 ALAHLLEAER
P23468 Receptor-type tyrosine-protein phosphatase delta 3 SPQGLGASTAEISAR
ILYDDGK
SYSFVLTNR
O00584 Ribonuclease T2 2 ELDLNSVLLK
VYGVIPK
P13521 Secretogranin-2 3 DQLSDDVSK
TSYFPNPYNQEK
VLEYLNQEK

















Fig. 3 Inter- (x-axis) and intraday (mean, y-axis) CV for each peptide 
illustrated as green (CV less than 20%) and red (CV greater than 
20%) dots. Failing peptides (red) are from the protein chitinase-3-like 
protein 1 (failed by inter-day, below horizontal line) and Seizure-6-like 
protein 1
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Discussion
The verification of biomarker candidates in CSF from 
discovery studies has been challenging due to the many 
issues pointed out in the introduction. One of the major 
bottlenecks has been to simultaneously measure a larger 
number of proteins in a high number of samples in a 
reproducible fashion and over time. In our view there is 
a need to develop well-described high-quality assays able 
to generate reproducible data over time, and ideally also 
between laboratories, in order to achieve efficient bio-
marker verification in CSF.
Recently, there has been at least two publications going 
in the direction of generating high-quality PRM assays for 
CSF-proteins; one describing assays for 30 brain proteins 
[30], and another assays for monitoring a set of defined 
biological process [31]. In our study, we have contributed 
towards this idea by developing 37 well-described high-
quality PRM peptide assays representing 21 proteins 
Fig. 4 Peptide amounts at different trypsin digestion times. Peptide amounts (mean ratio light/heavy) of the tested peptides at 16 h compared 
to 24 h (a) and 30 h (b). Green dots represent peptides with < 20% change after 16 h of digestion and CV < 20% between replicates, yellow dots 
represent peptides with < 20% change after 16 h digestion, but with CV > 20% between replicates and red dots represent peptides with > 20% 
change after 16 h digestion. Protein short name and the four first amino acids in the peptide sequence is shown for all peptides failing this test. The 
two peptides AQLLVVGSPGPVPR and ELDLNSVLLK are not included in this plot due to very high values compared to the rest. Measured abundance 
change at all time points are available in Additional file 8: Fig. S2
Fig. 5 Peptide digestion profile examples. Peptide amount (mean ratio light/heavy) at all tested digestion times for the peptides representing 
Neuronal cell adhesion protein (a all peptides passed) and Seizure-6-like protein 2 (b one peptide passed, one failed). Error bars represent min and 
max values measured. Similar digestion profiles of all tested peptides are available in Additional file 7: Fig. S1. The figure was created using R (http://
www.R-proje ct.org.) and ggplot2 (https ://ggplo t2.tidyv erse.org) 
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found to be affected in multiple sclerosis across multiple 
studies. Our goal is that these assays can be used to gen-
erate comparable data over time and provide the possibil-
ity to analyse and compare the protein levels in a large 
number of patient samples in a long-term perspective.
An important aspect of this work is that the biomarker 
candidates have been selected based on data from several 
studies using the online database CSF-PR. This approach 
is likely to provide less false positive candidates as more 
data, most often from several research groups, is used in 
the selection. Furthermore, the surrogate peptides have 
been selected based on quantitative information available 
from CSF-PR (when available), indicating that the par-
ticular peptide is actually regulated in the target protein. 
In sum, we argue that our approach is a step forward in 
increasing the effectiveness of verifying biomarker candi-
dates in CSF.
Selection of proteins and peptides—what is important 
to consider?
Using CSF-PR as a starting point for selecting proteins 
affected by MS differs substantially from using a single 
experiment as the basis for selection, and the 133 pro-
teins initially identified thus represents the proteins 
collectively reported to be affected by MS from the 
mass spectrometry proteomics literature. In our view, 
this approach increase the chance of including the 
most relevant proteins and those more likely affected 
by MS, compared to basing the selection on a single 
study.
Next, we wanted to make sure that all of the proteins 
included in the assay development was possible to quan-
tify in a PRM experiment without the need for protein 
depletion or peptide fractionation, as these steps both 
have their drawbacks. Targeted immunoaffinity deple-
tion of high-abundant proteins is a useful way to increase 
the chance of measuring low-abundant proteins. Deple-
tion is however a debated approach in biomarker studies, 
given that proteins not targeted by the depletion column 
may be co-depleted due to unspecific binding and pro-
tein interactions, potentially introducing a bias already at 
an early stage in the sample preparation [32–34]. As for 
peptide fractionation, this step will increase the analysis 
time, cost and complexity, and is therefore not desirable.
To arrive at a more manageable number, and as a dem-
onstration of our suggested workflow, we selected 25 
proteins. These proteins will of course not reflect all off 
the disease-affected processes represented by the com-
plete list of 120 proteins, nor are they meant to represent 
a final list of biomarker candidates for multiple scle-
rosis. However, they do cover a range of functions and 
processes relevant in the MS disease as summarized in 
Table 1.
Creating PRM assays for all peptides from all potentially 
interesting CSF‑proteins would be preferable, but as there 
will always be a cost vs. benefit consideration this 
is not realistic
Using the peptide level quantitative information available 
in CSF-PR as part of the surrogate peptide selection was 
also considered important. For the disease-affected pro-
teins we observed that not all of the peptides were regu-
lated in the discovery data, and that some peptides were 
also regulated in the opposite direction (Fig. 8). We sug-
gest inspecting and using the peptide level data available 
in CSF-PR to select peptides that are observed as signifi-
cantly changed, thus increasing the chance of the peptide 
actually representing the regulation reported at the pro-
tein level.
Different peptides from the same protein may show 
different (relative) abundance due to: (i) peptides map-
ping to multiple proteins or proteoforms with different 
regulation status, (ii) some peptides can be less suitable 
for mass spectrometry or in too low amounts for sta-
ble and accurate quantitation, and (iii) certain peptides 
have varying degrees of post-translational modifications, 
resulting in unstable concentration for the unmodified 

























CSF-PR Score / 100
Fig. 6 CSF-PR score (MS vs. Non-MS) compared to fold change from 
PRM comparison study (RRMS vs. OND). Comparison of the score 
found from CSF-PR (x-axis, score/100), representing the direction 
of change between MS and Non-MS in the literature, and the fold 
change (y-axis,  log2 transformed) found in our PRM study. Green 
dots represent peptides that were found significantly changed in the 
same direction in the literature and in the PRM study (passed) and 
red dots represent peptides that either were not significant or were 
significantly changed, but in opposite direction compared to the 
literature (failed). Protein short name and the four first amino acids in 
the peptide sequence is shown for all peptides failing this test
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guidelines for peptide selection in targeted proteomics, 
i.e. to avoid non-unique peptides and peptides prone to 
mis-cleavages.
Peptide stability testing—most peptides are stable 
across runs
A large majority of the tested peptides passed our stabil-
ity test, indicating that they are suitable for PRM moni-
toring robustly over time. We can conclude that they are 
in the appropriate concentration range in CSF for the 
Table 3 The most promising biomarker candidate proteins and peptides
Proteins and peptides passing all quality controls described in this study, thereby representing the most promising biomarker candidates for PRM assays. The table 
also shows if the protein is highest in MS or control, if calibration curves have been developed, and, if so, its linear area
Cal.curves: Calibration curves. MinLin: Lowest theoretical concentration that will be used for quantitation. MaxLin: Maximum theoretical concentration that will be 
used for quantitation
Accession Protein name Peptide sequence(s) Highest in Cal.curve MinLin (fmol/µl) MaxLin 
(fmol/µl)
P51693 Amyloid-like protein 1 WEPDPQR Control Yes 0.525 560
FQVHTHLQVIEER Control No
P61769 Beta-2-microglobulin VNHVTLSQPK MS No
P55290 Cadherin-13 YEVSSPYFK Control Yes 0.15 160
INENTGSVSVTR Control No
P16070 CD44 antigen ALSIGFETCR MS Yes 0.105 112
Q15782 Chitinase-3-like protein 2 LVCYFTNWSQDR MS Yes 0.045 48
LLLTAGVSAGR MS Yes 0.045 48
P10645 Chromogranin-A ILSILR Control No
SGELEQEEER Control Yes 0.75 800
EDSLEAGLPLQVR Control No
P12111 Collagen alpha-3(VI) chain EVYTFASEPNDVFFK MS No
P54764 Ephrin type-A receptor 4 VYPANEVTLLDSR Control Yes 0.075 80
NLAQFPDTITGADTSSLVEVR Control No
Q6MZW2 Follistatin-related protein 4 GPDVGVGESQAEEPR Control No
FDDYNSDSSLTLR Control No
VLQSIGVDPLPAK Control Yes 0.045 48
P48058 Glutamate receptor 4 NTDQEYTAFR Control Yes 0.09 96
P01591 Immunoglobulin J chain SSEDPNEDIVER MS No
Q92876 Kallikrein-6 DSCQGDSGGPLVCGDHLR Control Yes 0.15 160
P32004 Neural cell adhesion molecule L1 AQLLVVGSPGPVPR Control Yes 0.045 48
EGPGEAIVR Control No
Q9ULB1 Neurexin-1 DLFIDGQSK Control No
SDLYIGGVAK Control Yes 0.045 48
Q9P2S2 Neurexin-2 LSALTLSTVK Control Yes 0.045 48
GATADPLCAPAR Control No
AIVADPVTFK Control No
Q92823 Neuronal cell adhesion molecule AETYEGVYQCTAR Control No
SLPSEASEQYLTK Control Yes 0.15 160
VFNTPEGVPSAPSSLK Control No
Q9UHG2 ProSAAS ALAHLLEAER Control No
P23468 Receptor-type tyrosine-protein 
phosphatase delta
SPQGLGASTAEISAR Control No
SYSFVLTNR Control Yes 0.045 48
O00584 Ribonuclease T2 VYGVIPK MS No
P13521 Secretogranin-2 DQLSDDVSK Control Yes 0.045 48
VLEYLNQEK Control Yes 0.18 192
Q6UXD5 Seizure 6-like protein 2 FEAFEEDR Control No
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method to consistently provide a sufficient signal for sta-
ble measurements.
Chitinase‑3‑like protein 1 peptides give unstable 
measurements over time
Chitinase-3-like protein 1 (CH3L1) has been linked to 
several neurological diseases [23, 26, 35–39], includ-
ing MS [22, 24, 25, 27, 28]. However, it seems that this 
protein is not ideal for an absolute targeted assay, due 
to the unstable peptide measurements across runs. One 
explanation is that CH3L1 is low-abundant in many 
patient categories used in testing and as controls, but 
more abundant in MS patients. This may explain why 
several discovery studies have found it regulated [5, 24, 
25, 28] compared to controls and why we find high varia-
tions in this stability test using CSF from Control (OND) 
patients. Some peptides for CH3L1 were not far from 
being acceptable in terms of variation, having inter-day 
CV values between 20 and 30%. Due to the potential 
importance of this protein one could consider includ-
ing PRM assays for these peptides, but then taking into 
account that the variation in the data is larger.
Peptide digestion testing—most peptides show 
no increase after 16 h
Considering our goal of creating PRM assays able to 
measure absolute protein amounts, we found that it was 
crucial to examine the digestion status after the standard 
16 h of trypsin incubation. This is not a standard test for 
PRM assays, but in order for an assay to come as close 
as possible to reflect the absolute protein amount, we 
found it essential. For most proteins, digestion times of 
16  h were sufficient, in that no significant increase (or 
decrease) in peptide amount was observed after pro-
longed incubation. But there were a couple of peptides 
increasing also after 16 h of digestion, and nine proteins 
having some peptides passing and some failing the diges-
tion test (Fig. 4b).
When examining the full profile of peptide amount 
(L/H) measured after various trypsin incubation times 
(Additional file 7: Fig. S1), we also note that certain pep-
tides show a decrease already before 16  h of digestion. 
Although, no decrease beyond 20% was observed before 
Fig. 7 Calibration curve for the peptide YEVSSPYFK from the protein 
Cadherin-13 in rat plasma. Blank values (blue) indicates abundance 
of background without spike-in of endogenous peptide but spike-in 
of heavy. Spiked samples (green) have both endogenous and 
heavy spike in. The linearity of the lowest concentrations is shown 
in the smaller graph for increased visibility. The experiments were 
conducted in trypsinated triplicates. The figure was created using R 
(http://www.R-proje ct.org) and ggplot2 (https ://ggplo t2.tidyv erse.
org) 
Fig. 8 Illustration of the peptide quantitative data from one dataset in CSF-PR for the protein Secretogranin-2. Quantified peptide sequences are 
displayed as green or red boxes, covering various segments of the protein sequence (grey) from N- to C-terminal. Dark red and dark green indicate 
peptides that are significantly different between the compared disease groups, and light red and light green indicate non-significant peptides. 
Arrows and red circles indicate selected peptides for this particular protein in the assay development
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16 h, this may still indicate that some undesired peptide 
degradation is occurring already before 16 h. Such “fast 
digesting” peptides should ideally have shorter trypsin 
incubation times. For the peptides where the digestion 
was not completed after 16 h, one could envision longer 
digestion times in order to reach complete digestion, or 
consider testing other digestion conditions. However, 
applying individual trypsin digestion times and condi-
tions for a large number of peptides in assays run over 
time is tedious and unrealistic. The peptides where the 
digestion was not complete after 16 h are not suitable for 
absolute quantification, but the assays could still be used 
for relative quantitation if trypsin incubation times are 
equally long between experiments. An alternative would 
be to search for other peptides better representing these 
proteins when using 16 h digestion time.
The overall results from the digestion testing show that 
each peptide can have specific physiochemical proper-
ties affecting the digestion process and demonstrate the 
necessity of obtaining peptide digestion profiles for each 
individual peptide. Another approach could be to use iso-
topically labelled proteins as internal standards, instead 
of peptides, in which case digestion variability would be 
adjusted for by the internal standard. This is however a 
quite costly approach.
PRM RRMS vs control—confirmation of previously found 
changes
This small PRM study was designed to investigate 
whether the selected peptides could reproduce the pre-
viously reported quantitative differences between MS 
and controls. As we had merged some of the disease sub-
categories when performing the initial CSF-PR search, 
it was not possible to find identical MS and control 
groups. We concluded that using relapsing–remitting MS 
(RRMS) and OND controls, was a good choice for this 
experiment.
Most of the peptides also passed this test, but seven 
peptides did not show the same significant difference 
between RRMS and OND as reported between MS and 
Non-MS in the CSF-PR publications [14], either because 
the difference was not significant or they showed the 
opposite change. One reason may be that the number of 
patients included in both the PRM study described here 
and the studies in CSF-PR is not large enough to elimi-
nate the biological variation as a factor, creating false 
positive biomarker candidates. The patient groups used 
were also not identical, which could result in variation in 
differentially abundant proteins.
Another reason for the discrepancy may be that many 
of the studies in CSF-PR used depletion of high-abundant 
proteins, which on purpose was not performed in our 
PRM pilot experiment. Depletion could potentially affect 
the protein quantitation and thereby the resulting differ-
entially abundant proteins as variation is introduced, as 
discussed above. This is particularly relevant if the num-
ber of patients is low. Even though the seven rejected 
peptides did not pass this test, they could still prove 
valuable upon more thorough testing with larger patient 
numbers. In the current study, the 37 peptides display-
ing similar differential abundance as previously reported 
were prioritized.
Development of calibration curves—linearity down to the 
highest dilution point
Calibration curves were generated in rat plasma as it is a 
somewhat similar matrix to CSF and from a different spe-
cies (non-human CSF was not possible to obtain), so that 
there would be no endogenous presence of analyte signal 
in the matrix, which would add to the spiked signal [40]. 
The calibration curves displayed a high degree of linear-
ity down to the highest dilution point, with adjusted  R2 
values all over 0.99. Ideally, the calibration curves would 
include endogenous analyte concentrations so that the 
signal would be indistinguishable from the background, 
yielding a hockey-stick shape of the curve. The % CV of 
the replicates of the lowest endogenous peptide concen-
trations was less than 20% for all but one peptide, indi-
cating that the limit of quantification (LOQ) was not 
reached for these. As the analyte concentrations rarely 
varies more than the span covered by the linear curve, 
the assays were deemed sufficient for our purposes, and 
the concentration span between the lowest and high-
est measured endogenous concentration will be used for 
absolute quantitation.
Relevance for multiple sclerosis and other neurological 
disorders
The assays have been developed to monitor processes 
affected by MS, but through CSF-PR, we find that sev-
eral of the protein candidates are also found changed in 
Alzheimer’s and Parkinson’s disease. This is the case for 
nine of the 21 proteins having peptides that passed all 
test (CD44 [41], Follistatin-related protein 4 [41], Secre-
togranin-2 [31, 42] ProSAAS [42], Neurexin-1 [31], Cad-
herin-13 [43], Kallikrein-6 [44], Amyloid-like protein 1 
[44] and Ephrin type-A receptor 4 [44]). It indicates, not 
surprisingly, that many of the processes affected by MS 
are also affected by other neurological disorders, and are 
thus not specific to MS. Which in turn can mean that the 
diagnostic value of these particular proteins is limited, 
however they could still be very valuable as biomarkers 
for disease status, treatment effect and prognosis.
Validation in larger cohorts using the developed assays 
is necessary to determine the value of the proteins as bio-
markers in a clinical setting. After validation of a subset 
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of the proteins using PRM, one likely way to implement 
the measurement of the proteins into the clinic would be 
to develop ELISA-assays for the most valuable proteins. 
In the future the PRM-assays could perhaps also be used 
directly in the clinic.
It is also expected that these assays will be useful in 
shedding light on the disease status for other diseases 
where similar processes are affected. The remaining 12 
proteins with peptides that passed all tests are however 
only changed in the MS categories in CSF-PR. These 
proteins may therefore be the most useful for diagnostic 
purposes and monitoring of processes occurring specifi-
cally in MS patients. For more details, the proteins can be 
searched and available data investigated in CSF-PR.
Conclusion
In this study, we have developed 37 robust PRM pep-
tide assays for 21 CSF proteins likely affected by MS. The 
selected proteins cover many of the pathways and pro-
cesses recently reported to be affected in MS, but also 
in other neurological diseases such as Alzheimer’s and 
Parkinson’s disease. The peptides chosen as protein sur-
rogates are quantifiable without the need for depletion, 
fractionation or enrichment prior to mass spectrom-
etry. Due to the documented inter- and intra-day stabil-
ity of the assays and the digestion stability, comparable 
quantitative values over time is expected. This allows for 
large-scale analyses of patient samples to reveal the rela-
tionship between the monitored MS-affected processes, 
disease progression and treatment response, and results 
from future large-scale patient analyses using these 
assays are expected to aid in treatment decisions.
These well-documented absolute quantitative assays 
could also be adopted by other laboratories and have the 
potential to generate comparable quantitative measure-
ments between laboratories. To explore this potential 
future, inter-laboratory comparisons must be conducted.
We recommend that the presented workflow should 
be used as a general guideline for the development of 
targeted PRM biomarker assay in CSF, and consider this 
work to be a contribution towards standardizing CSF pro-
tein quantification allowing us to move from non-compa-
rable data between single experiments to accumulation of 
reproducible quantitative data over time. In our view this 
is essential in order to enable the analyses of large enough 
patient cohorts to reveal disease-related changes in the 




Human cerebrospinal fluid (CSF) was obtained by diag-
nostic lumbar puncture, according to the standardized 
protocol for collection and biobanking [45]. Patients 
gave written consent and the study was approved by 
the Regional Committee for Medical Research Ethics 
of Western Norway. Various pools of CSF were used in 
the experiments described in this paper, mainly due to 
the limited availability of CSF samples to use for assay 
optimization and testing. Details about the pools can be 
found in Table 4 and in [5]. The same pools as in [5] were 
used for the MS vs. Control PRM study (MS and OND 
pools, here: Pools 3–8). The pool used for the DDA pro-
teome depth and peptide stability experiment consisted 
of various OND patients (Pool 2), the pool used in the 
digestion test consisted of 3 OIND patients (Pool 1, all 
with myelitis).
Rat plasma
Rat plasma (P2516, Sigma Aldrich) was used to construct 
calibration curves for high-purity peptides. The pur-
chased rat plasma contained lyophilized material derived 
from 1 ml pooled and filtrated rat blood with the addition 
of anticoagulant, 3.8% trisodium citrate. The concentra-
tion of the rat plasma was estimated by BCA, and diluted 
in 1xPBS to a final concentration of 0.5  µg/µl prior to 
trypsination.
Literature curation using CSF‑PR
We used CSF-PR (https ://prote omics .uib.no/csf-pr) to 
extract biomarker candidates between MS and non-
inflammatory control patients (Non-MS) as of August 
2017. To specifically extract quantitative data rel-
evant to this comparison, we first merged certain MS 
and control subcategories listed in CSF-PR as follows: 
RRMS (relapsing-remitting MS), CDMS (clinically 
Table 4 Overview of cerebrospinal fluid pools used in the various experiments
RRMS: Relapsing-remitting multiple sclerosis; OIND: Other inflammatory neurological diseases; OND: Other neurological diseases; DDA: data-dependent acquisition
Name #Patients each 
pool
Female/Male Disease category Average age Used in experiment
Pool 1 3 2/1 OIND 35.3 Peptide digestion test
Pool 2 N/A N/A OND N/A DDA + peptide stability test
Pool 3–5 7 18/3 RRMS 36.8 PRM RRMS vs. control
Pool 6–8 7 18/3 OND 35.4 PRM RRMS vs. control
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definite MS) and CIS-MS (clinically isolated syndrome 
with conversion to MS) were merged to the general 
category “MS” and the subcategories OND (other neu-
rologically controls), symptomatic controls, Non-MS, 
healthy and healthy controls were all merged to the 
general category “Non-MS”. In this way we identified 
protein data from all papers in the resource compar-
ing MS to non-inflammatory controls. The protein 
table with the quantitative data from these studies 
contained thousands of proteins, so we applied some 
selection criteria by using the table filtering options in 
CSF-PR before exporting the protein list: (i) proteins 
quantified in at least two studies and (ii) having a CSF-
PR score () of >=0.5 (50%) or < = − 0.5 (− 50%) accord-
ing to the equation used in CSF-PR for summarizing 
overall reported protein regulation (see below, ×100 
for %), indicating that each protein was increased or 
decreased in at least 50% when averaging the results 
from all studies.
This resulted in 194 proteins, which were exported 
from CSF-PR, and further analysis was performed 
using Excel. To identify the most consistently changed 
proteins, we applied an additional criterion that (iii) 
proteins were found changed in the same direction (up 
or down) in at least two studies. This reduced the list 
to 133 proteins (Additional file 1: Table S1), represent-
ing the most promising and consistently reported bio-
marker candidates for MS. A separate list of proteins 
that were significantly changed between MS and Non-
MS, but quantified in only one study in CSF-PR was 
also created (Additional file 2: Table S2).
CSF sample preparation—general
Protein concentration in the CSF pools was measured 
by the QubitTM fluormeter (InvitrogenTM, Thermo 
Scientific) and the Qubit™ protein assay kit (Invitro-
genTM, Thermo Scientific), following the manufactur-
ers protocol. CSF samples were lyophilised at 30 °C in 
an Acid-Resistant CentriVapTM Concentrator System 
(LabconcoTM), and dissolved in 20  µl freshly made 
Urea solution (8 M Urea/20 mM methylamine (Sigma 
Aldrich)). All CSF samples were in-solution digested 
as previously described [4] using trypsin porcine (Pro-
mega, art. V5111) added to samples in a 1:50 rela-
tionship, and desalted using OASIS ® HLB µElution 
plates  30  µm (Waters Corp, Millford, MA, USA) 
according to the manufacturer’s instructions. Samples 
were vacuum dried following desalting, and dissolved 
in 2% ACN, 0.1% TFA to a concentration of approxi-
mately 0.5  µg/µL for the MS analysis. About 0.5  µg 
were injected if not otherwise stated.
Preparation and spike‑in of synthetic peptides
All isotopic labelled peptides (IS peptides) used as inter-
nal standards were purchased from Thermo Scientific 
at crude (unknown purity) and AQUA Ultimate (> 95% 
purity) quality for peptide testing and AQUA Ultimate 
quality only for calibration curves, whilst synthetic light 
peptides (SpikeTides) were acquired from JPT. Heavy 
labelled peptides have been C-terminally modified 
with 13C and 15  N isotope arginine or lysine. The syn-
thetic heavy peptides were added to the samples before 
the desalting step, and the synthetic light peptides from 
JPT used to make calibration curves were added prior to 
digestion as they contain a tag that needs to be enzymati-
cally released. Heavy peptides were spiked to the samples 
in an approximate 1:1 relationship between the heavy 
IS peptide and the endogenous analyte, which was esti-
mated from initial peptide tests (data not shown). Nota-
bly, the lowest endogenous concentration was adjusted to 
3 fmol/µg. Spike-in for calibration curve development is 
described under “calibration curve” section.
PRM mass spectrometry—general for all PRM experiments
The separation of peptides was performed by an Ulti-
mate™ 3000 RSLCnano System (Thermo Fisher Sci-
entific™) with an Acclaim PepMap™ 100 trap column 
(diameter width at 75 µm × 2 cm nanoviper C18 column, 
with particle size 3 µm and length at 100 A) and 5 µL 0.1% 
TFA solution. Peptides were separated on an analytical 
column PepMapTM RSLC C18 (diameter width 75 µm × 
50 cm, particle size at 2 µm and 100 A in length) with the 
combination of 95% solvent A (0.1% FA) and 5% solvent 
B (100% ACN, 0.1% FA) with a flow rate of 200 µl/min. 
The column gradient for peptide elution went from 0 to 
5 min with 5% solvent B, then an increase at 5–5.5 min 
to 8% of solvent B, 5.5–140 min 35% B, 140–155 min 90% 
B and 155–170  min 90% B. At 170–175  min solvent B 
decreased to 5% B and held at 5% solvent B from 175 to 
190 min. Column temperature was specified to be 35 °C, 
whilst the auto sampler had a temperature of 4 °C. Ioni-
zation of samples occurred with an Easy-Spray™ (Thermo 
Scientific) ion source, with a spray voltage at 1.8 kV. The 
capillary temperature was set at 250  °C, heater temper-
ature at 350  °C, whilst the S-lens RF value were at 60. 
Sheath and auxiliary gases were not used. As a result of 
the ion source, samples were obtained in a positive ioni-
zation mode.
Mass spectrometry analysis
The method duration was 195  min (runtime 
10–175  min). The mass spectrometer was operated in 
PRM scheduled mode and switched between full scan 
MS1 between every 12th PRM MS2 scan. The instrument 
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was controlled through Q Exactive HF Tune 2.4 and 
Xcalibur 3.0. MS1 spectra were acquired in profile mode 
in the scan range of 375–1500  m/z with resolution of 
15,000, automatic gain control (AGC) target of 3e6, and 
a maximum injection time (IT) of 15 ms. The target pep-
tides on the inclusion list were sequentially isolated for 
higher-energy collision dissociation (HCD) fragmenta-
tion and MS2 acquisition to a normalized HCD collision 
energy of 28%, target AGC value of 1e5, resolution R = 15 
000, and IT of 100  ms. The precursor isolation window 
was set to 1.6  m/z with no isolation offset or dynamic 
exclusion. Lock-mass (445.12003  m/z) internal calibra-
tion was used.
Skyline analysis
Skyline [29] was used for the creation of inclusion lists 
prior to PRM-mass spectrometry analysis and for data 
refinement of the PRM-mass spectrometry data. Sky-
line settings were overall kept at default, or updated 
depending on the parameters in the mass spectrometry 
analysis used to acquire data. Notably, structural modi-
fications were specified with carbamidomethyl (C) and 
isotope modification “label: 13C(6) 15  N(2) (C-term 
K)” and label: “13C(6) 15 N(4) (C-term R)”. Both 2+ and 
3+ charged precursors and b- and y-ions were inves-
tigated in the stability test experiment, while in the fol-
lowing (digestion, MS vs. OND and calibration curves), 
only 2+ precursors and y-ions were used, as these most 
often gave the best signal. Detailed Skyline settings for 
each experiment, e.g. the peptide and transition settings 
and filters, can be inspected in the Skyline documents 
uploaded to Panorama Public (https ://panor amawe b.org/
PRM_Assay _CSF.url).
The peak signal for each peptide was determined by 
the Skyline peak picking algorithm, and manually veri-
fied or re-integrated based on the fragment pattern of the 
peptide, elution profile and simultaneous retention time 
of the endogenous and the IS peptide. Spectral librar-
ies from CSF samples generated on the same Q Exactive 
HF instrument were used as a reference to make sure the 
correct peak for the various peptides were chosen. The 
three fragments with the highest intensity, low interfer-
ence, and mass error less than 10 ppm was selected for 
quantitation. Additional file  13: Fig.  S4A and B shows 
examples of typical transitions used in the assay. All other 
transitions can be inspected in Panorama Public (https ://
panor amawe b.org/PRM_Assay _CSF.url) where the Sky-
line documents from all experiments can be downloaded.
Notably, for most peptides, one to three of the tran-
sitions were significantly more intense compared to 
the rest, only the top three where therefore chosen for 
quantification. A typical example of this is illustrated 
in Additional file 13: Fig. S4C and D. For some peptides 
in certain tests or replicates, only two transitions were 
used for quantitation, due to missing data or bad peaks 
in specific replicates. These were mainly from very low 
abundant proteins and/or from peptides with only low 
intensity transitions. The area under the curve, excluding 
background, were summed to give one peak area value 
for each peptide.
Furthermore, the endogenous peak area was divided by 
the peak area of the heavy internal standard peptide to 
generate a ratio to standard which was used for quanti-
tation. From Skyline, a.csv file was exported containing 
the quantitative data needed for follow-up processing 
in Microsoft Excel or R. To determine the difference 
between the two patient groups in the final PRM experi-
ment, an unpaired two tailed, homoscedastic student’s 
t test was performed using Microsoft Excel. A p-value 
of ≤ 0.05 was used to determine a significant difference.
CSF protein depth investigation
We tested the identification of CSF proteins from a 20 µg 
un-depleted CSF sample (pool 2) subjected to peptide 
fractionation into 11 fractions following trypsin diges-
tion (as described above). Peptide fractionation was per-
formed by mixed mode reversed phase-anion exchange 
chromatography (MM) [18] on a Promix MP column 
(MP10.250.0530, 1.0 × 250 mm, 5 μm, 300 Å, Sielc Tech-
nologies), as previously described [33].
Data dependent acquisition mass spectrometry analysis
Approximately 0.5 μg of peptides from each fraction was 
injected into the same LC system, trap column and mass 
spectrometer as described above. However, a 25 cm ana-
lytical column (PepMap RSLC, 25 cm × 75 μm i.d. EASY-
spray column, packed with 2  μm C18 beads (Thermo 
Scientific)) was used (flow rate of 0.250 μL/min). Solvent 
A and B was the same as above as was the other MS gen-
eral instrumental parameters related to ionization, volt-
age, temperature etc.
The mass spectrometer was operated in data-depend-
ent acquisition mode to automatically switch between 
full scan MS1 and MS2 acquisition. The method duration 
was 120  min (runtime 8-105  min). The instrument was 
controlled through Q Exactive HF Tune 2.4 and Xcalibur 
3.0. MS spectra were acquired in the scan range of 375–
1500 m/z with resolution of 60 000, automatic gain con-
trol (AGC) target of 3e6, and a maximum injection time 
(IT) of 25 ms. The 12 most intense eluting peptides above 
intensity threshold 5e4, and charge states two or higher, 
were sequentially isolated for higher-energy collision dis-
sociation (HCD) fragmentation and MS2 acquisition to 
a normalized HCD collision energy of 28%, target AGC 
value of 1e5, resolution R = 60,000, and IT of 110  ms. 
The precursor isolation window was set to 1.6 m/z with 
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an isolation offset of 0.3 m/z and a dynamic exclusion of 
20 s. Lock-mass (445.12003 m/z) internal calibration was 
used and isotope exclusion was active.
Data processing
All raw files were converted to mgf using ProteoWizard 
[46] and searched using X! Tandem [47], MyriMatch 
[48] and MS Amanda [49] via SearchGUI (v2.1.3) [50] 
against the homo sapiens complement of the UniProt/
SwissProt reviewed database downloaded October 2015 
(20 196 entries) [17] with the reversed version of every 
sequence added as decoys. The search settings were: 
carbamidomethylation of C; oxidation of M as variable 
modification; trypsin as enzyme with a maximum of two 
missed cleavages; precursor charge 2–5; peptide length 
6–30; precursor mass tolerance 10  ppm and fragment 
mass tolerance 0.005 Dalton. All other settings were left 
as the defaults. The search engine results were combined 
and assembled in PeptideShaker [51] (v1.1.2). Hits were 
thresholded to retain only the best scoring until a false 
discovery rate (FDR) of 1% was reached, estimated using 
the distribution of target and decoy hits [52].
Peptide stability test
To test the intra- and inter-day variability of measure-
ments for the peptides, we analysed aliquots from the 
same CSF samples (pool of OND patients) at two differ-
ent time points at the same day across 5 days. Two 10 µg 
aliquotes of CSF-pool 2 were in-solution digested, spiked, 
desalted, dried and stored in − 20 °C. This was repeated 
on five different days, and all samples were analysed by 
PRM MS as described above. Data was inspected and 
refined in Skyline as described above, and in Excel, the 
intra- and inter-day variation for each peptide (2+ and 
3+ separately) was calculated on the exported total 
area ratio (light/heavy). This value for each peptide was 
compared between samples prepared on the same day 
(intra-day) and between each of the three sample sets 
(inter-day). Peptides with intra- and inter-day CV less 
than 20% was considered reproducible.
Peptide digestion test
Fifteen 10  µg aliquots of CSF-pool 1 was in-solution 
digested, spiked, and desalted as described above. Trypsi-
nation was however, stopped at five different time points 
(1, 5, 16, 24 and 30 h), and three replicates was stopped 
at each time point. This experiment was repeated three 
times (across three different weeks). Data was refined in 
Skyline, as described above and the percentage change in 
ratio to standard was calculated for each peptide between 
16 to 24 h and 16 to 30 h. A peptide was considered stably 
trypsinated after 16 h if the percentage change from 16 to 
14 h, and 16 to 30 h was less than 20%. Individual protein 
plots showing ratios at all time points for all peptides 
were generated using R (http://www.R-proje ct.org). The 
plots were generated using the graphics package ggplot2 
(https ://ggplo t2.tidyv erse.org) (Additional file 7: Fig. S1).
PRM RRMS vs control
Samples from six CSF-pools were used in this experi-
ment. The samples were crude 100 µg aliquotes from the 
experiment described in [5], which was three pools of 
MS patients and three pools of OND patients (pools 3-8). 
The samples were purified and concentrated using 3 kDa 
ultracentrifugation filters as described in [53], before 
in-solution digestion and Oasis desalting as described 
above, except a 10 mg plate was used, as in [53], due to 
the high protein amount (100  µg). The eluate after the 
desalting was divided to 5  µg aliquots and two aliquots 
(replicates) from each pool was used for this experiment. 
The aliquots were spiked with heavy peptides, dried and 
dissolved in 2% ACN, 0.1% TFA to approximately 0.5 µg/
µL. Approximately 1  µg sample was injected for MS 
analysis and analysed by PRM as described, except MS2 
resolution was 30,000. The ratio to standard was used to 
calculate fold change and significance between groups.
Development of calibration curves
Calibration curve generation in rat plasma
The calibration curves were made in rat plasma by pre-
paring a dilution series of synthetic normal mass (light) 
peptides based on the estimated endogenous concentra-
tion of each peptide in CSF Pool 2. An 11-point dilution 
curve was centered around this estimate, so that the var-
ying analyte spanned 32 times the endogenous concen-
tration and 32 times less than the estimated endogenous 
concentration. The dilution series was prepared for the 
synthetic light peptides for analysis in rat plasma (dilu-
tions prepared in 8 M Urea/20 mM methylamine directly 
prior to trypsination), Additionally, a mix of heavy 
AQUA peptides in levels 1:1 with endogenous peptide 
was generated in 5% ACN. Eleven 10  µg aliquots of rat 
plasma were added synthetic light peptides in different 
dilutions. In addition, one sample without added light 
peptides and was used as a blank. The twelve samples 
were in-solution trypsin digested, and equal amounts of 
the AQUA heavy peptides mix were added to each sam-
ple prior to desalting. This procedure was performed in 
trypsinated triplicates.
Mass spectrometry analysis
For the calibration curve experiment, some optimized 
parameters were used in the PRM analysis. Peptides were 
separated on an analytical column PepMapTM RSLC 
C18 (diameter width 75  μm × 25  cm, particle size at 
2 μm and 100 A in length) with the combination of 95% 
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solvent A (0.1% FA) and 5% solvent B (100% ACN, 0.1% 
FA) with a flow rate of 250 μl/min. The column gradient 
for peptide elution went from 0 to 5  min with 5% sol-
vent B, then an increase at 5–5.5 min to 7% of solvent B, 
5.5–65 min 22% B, 65–87 min 35% B, 87–92 min 90% B 
and 92–102 min with 90% B. At 102–105 min solvent B 
decreased to 5% solvent B and held a 5% solvent B from 
105 to 120  min. The method duration for calibration 
curve runs was 120 min (runtime 10–110 min). The mass 
spectrometer was operated and MS spectra acquired as 
described above for PRM analysis, except MS2 spectra 
were acquired with optimized collision energies, reso-
lution R = 60,000 at 200 m/z, IT of 118 ms, AGC target 
value at 2e5 and precursor isolation window was set to 
0.7 m/z. All other parameters related to the LC and MS 
instrumentation and settings were as described above for 
general PRM experiments.
Calibration curve development in R
Following data refinement in Skyline, the ratio to stand-
ard values were exported for analysis in the programming 
language R (http://www.R-proje ct.org). For the peptides 
measured in rat plasma, the measured ratio to standard 
was multiplied with the spike-in level to give the meas-
ured concentration at each dilution point and was plotted 
against the theoretical concentration. Notably, as more 
variation is common in the high concentration measure-
ments, the linear regression was weighted with 1/sd^2 to 
limit the impact of the points with the highest variability 
on the regression equation [40]. The slope, intercept and 
the lowest and highest theoretical concentration points 
of the linear curve was exported. The plots were gener-
ated using the graphics package ggplot2 (https ://ggplo 
t2.tidyv erse.org).
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